XBIO

1.4009.09%
DD

Dmitry Dmitrievich Genkin

Chairman

Dr. Dmitry Dmitrievich Genkin, M.D., serves as Non-Executive Director and Chief Scientific Officer at Santersus AG. He has been Non-Executive Director of Xenetic Biosciences Inc. since December 6, 2023 and serves as its Chairman. Dr. Genkin served as Director of Xenetic Biosciences, Inc. since August 14, 2017 until July 15, 2021. Dr. Genkin served as Scientific Consultant and Observer of Xenetic Biosciences, Inc. since May 3, 2016 until August 15, 2017. Dr. Genkin previously served on the Board of Directors from 2004 to 2016 of Xenetic Biosciences, Inc. Dr. Genkin is a Partner and Director of FDS Pharma, which is listed on the Moscow stock exchange. Since 2005, Dr. Genkin has served as Executive Chairman of PJSC Pharmsynthez, a public company and Xenetic’s majority stockholder. He was a Member of Scientific Advisory Board of Xenetic Biosciences, Inc. until 2019. Dr. Genkin served as a Non-Executive Director of Xenetic Biosciences, Inc. since September 2015 until May 3, 2016. He served as Director of VBI Vaccines Inc. from July 9, 2015 to May 6, 2016. Dr. Genkin is founder and board member of Santersus AG – a Swiss private pharmaceutical company developing novel apheresis therapies for unmet medical need indications. Dr. Genkin is on the board of CLS Therapeutics Inc. and Peri-Ness Ltd. – private biotechnology companies developing anti-NETosis therapies. He has the Russian equivalent of an MD in Internal Therapy and studied drug delivery under Professor Gregoriadis at The School of Pharmacy, University of London in 1992 and the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm from 1992 to 1993. Since 1993, Dr. Genkin has headed a number of Russia's largest pharmaceutical companies including Pharmavit, which had 27% of the Russian pharmaceutical market. In 1998, he was awarded the silver medal by the Russian Natural Science Academy.

Positions